US 12,202,888 B2
High-affinity Mycobacterium tuberculosis capsule-specific human monoclonal antibody
Jacqueline M. Achkar, Brooklyn, NY (US); Jonathan Lai, Dobbs Ferry, NY (US); Elise Ishida, Aiea, HI (US); Daniel Hofmann, Moembris (DE); and Tingting Chen, Bronx, NY (US)
Assigned to Albert Einstein College of Medicine, Bronx, NY (US)
Filed by Albert Einstein College of Medicine, Bronx, NY (US)
Filed on Apr. 28, 2023, as Appl. No. 18/309,590.
Application 18/309,590 is a division of application No. 17/247,532, filed on Dec. 15, 2020, granted, now 11,643,455, issued on May 9, 2023.
Application 17/247,532 is a continuation in part of application No. 17/047,256, abandoned, previously published as PCT/US2019/027218, filed on Apr. 12, 2019.
Claims priority of provisional application 62/739,428, filed on Oct. 1, 2018.
Claims priority of provisional application 62/657,253, filed on Apr. 13, 2018.
Prior Publication US 2023/0365663 A1, Nov. 16, 2023
Int. Cl. C07K 16/12 (2006.01); G01N 33/53 (2006.01); G01N 33/543 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/1289 (2013.01) [G01N 33/5302 (2013.01); G01N 33/54388 (2021.08); G01N 33/5695 (2013.01); A61K 2039/505 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01)] 19 Claims
OG exemplary drawing
 
1. An assay device for selectively detecting Mycobacterium tuberculosis (Mtb) bacteria or Mtb arabinomannan (AM) in a biological sample, wherein the assay device is a lateral flow assay device or an Enzyme Linked Immunosorbent Assay (ELISA), the assay device comprising:
(a) a first portion comprising a first plurality of anti-Mtb AM antibodies, or Mtb AM-binding fragments thereof, wherein each anti-Mtb AM antibody, or Mtb AM-binding fragment thereof, comprises a heavy chain variable region and a light chain variable region, wherein each of the heavy chain and the light chain variable regions comprises a CDR1, CDR2, and CDR3; and wherein:
(i) the sequence of CDR1 of the heavy chain comprises SEQ ID NO: 1; the sequence of CDR2 of the heavy chain comprises SEQ ID NO:2; the sequence of CDR3 of the heavy chain comprises SEQ ID NO:3; the sequence of CDR1 of the light chain comprises SEQ ID NO:4; the sequence of CDR2 of the light chain comprises SEQ ID NO:5; and the sequence of CDR3 of the light chain comprises SEQ ID NO:6; or
(ii) the sequence of CDR1 of the heavy chain comprises SEQ ID NO: 1; the sequence of CDR2 of the heavy chain comprises SEQ ID NO:2; the sequence of CDR3 of the heavy chain comprises SEQ ID NO:45; the sequence of CDR1 of the light chain comprises SEQ ID NO:4; the sequence of CDR2 of the light chain comprises SEQ ID NO:5; and the sequence of CDR3 of the light chain comprises SEQ ID NO:6,
wherein the anti-Mtb antibodies, or Mtb AM-binding fragments thereof, are each attached to their own reporting entity; and
(b) a second portion comprising a second plurality of anti-Mtb AM antibodies, or Mtb AM-binding fragments thereof.